TrialClinical and translational science2025

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.

Ashley L Lennox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.